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High-dose glucocorticoid treatment of
near-fatal bocavirus lung infection
results in rapid recovery
To the Editor:
Human bocavirus (HBoV), which belongs to Parvoviridae, is a well-defined pathogen of respiratory
infections, particularly in young children [1]. In contrast, the frequency of HBoV infections in adults with
respiratory symptoms is virtually unknown and its causative role in respiratory failure is debated [1, 2].
Furthermore, the observation that dexamethasone is beneficial in COVID-19 patients with respiratory
failure requiring respiratory support has gained great interest [3]. However, whether glucocorticoid
treatment is useful in other severe viral respiratory diseases is a matter of controversy [4].
Here, we report on a 58-year-old, obese (body mass index 35 kg·m−2, Eastern Cooperative Oncology
Group performance status 1), Caucasian male who presented at Charité University Hospital (Berlin,
Germany) on 25 February 2020 with a 6-day history of fever and shortness of breath. 3 months earlier, he
had received BEAM (carmustine, etoposide, cytarabine and melphalan) high-dose chemotherapy and
autologous stem cell transplantation (autoSCT) for relapsed Hodgkin’s lymphoma, resulting in complete
remission. Relevant medical history included psoriasis, diabetes mellitus type 2, permanent atrial
fibrillation and COPD of Global Initiative for Chronic Obstructive Lung Disease stage II, with no relevant
previously documented pulmonary structural alterations. Concomitant medication on admission consisted
of acyclovir, pantoprazole, digitoxin, bisoprolol, sitagliptin, metformin, insulin and acitretin, all not
considered as causative for the clinical symptoms. On admission, peripheral oxygen saturation
demonstrated hypoxaemia (SpO2 88%), C-reactive protein (CRP) level was 50.9 mg·L
−1 (normal range
<5 mg·L−1), and chest radiography disclosed diffuse reticular, interstitial infiltrations of the lung. As the
patient deteriorated, accompanied by further CRP increase to 92.9 mg·L−1, during a 7-day course (25
February to 3 March) of antibiotic treatment with piperacillin/tazobactam and ciprofloxacin, a subsequent
lung computed tomography (CT) scan (figure 1a) revealed bilateral pulmonary infiltrates with interstitial
pattern, ground-glass opacities, (pre-existing) bullae and consolidation in the upper-left lobe.
Small-volume bronchoalveolar lavage (BAL) and lung biopsy were performed. On 5 March, the patient
finally required mechanical ventilation due to respiratory failure without signs of overt sepsis, with an
initial positive end-expiratory pressure of 5 cmH2O; arterial oxygen tension/inspiratory oxygen fraction
ratio was 136 mmHg, suggesting moderate acute respiratory distress syndrome (ARDS). Extended
examinations of the BAL for infectious pathogens (bacterial culture and microscopy; and PCR-based
respiratory panel analyses including various infectious agents (viruses (adenovirus, HBoV,
cytomegalovirus, coronavirus including severe acute respiratory syndrome (SARS) coronavirus 2,
Epstein–Barr virus (EBV), entero/rhinovirus, human herpesvirus 6, herpes simplex virus (HSV)-1 and
HSV-2, influenzavirus A/B, metapneumovirus, parainfluenzavirus 1–4, respiratory syncytial virus A/B,
varicella zoster virus), bacteria (Bordetella spp., Chlamydia spp., Legionella spp. and Mycoplasma spp.) and
Pneumocystis jirovecii)) revealed positivity for HBoV (and low-level detection of EBV (2390 copies (cp) per
mL) in BAL but not in blood, judged not to be clinically relevant) but no other pathogens.
We considered HBoV infection followed by excessive immune response, possibly aggravated by immune
reconstitution after autoSCT, as underlying pathogenic events. A high concentration of HBoV genome
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copies (3.2×108 cp·mL−1 in BAL), HBoV detection by fluorescence in situ hybridisation (figure 1b) and
pronounced T-lymphocytic infiltrates (figure 1c and d) in the lung tissue confirmed this scenario. Given
the lack of HBoV-specific treatments, we aimed to mitigate the immune reaction and subsequent
pulmonary damage by pulsed high-dose glucocorticoid therapy (5 March (day 1), 500 mg prednisolone;
days 2 and 3, 1000 mg methylprednisolone) followed by rapid reduction to 20 mg·day−1 prednisolone and
tapering. Respiratory parameters and radiological findings improved rapidly (figure 1e and f), allowing
termination of mechanical ventilation on day 4 (8 March) of intensive care unit treatment and discharge
on 17 March. In parallel to the clinical improvement, CRP values rapidly decreased and remained normal.
A CT scan 2 months after treatment confirmed complete resolution of all infiltrates (figure 1g).
Given the virtually unknown frequency of HBoV in adult patients with respiratory symptoms [1], we
retrospectively analysed a total of 5328 consecutive adult respiratory samples, mainly consisting of
tracheobronchial secretions and BALs, and which were all examined by PCR-based respiratory panel
analyses, for HBoV. We identified 17 HBoV-positive patients, most of them heavily immunocompromised.
Given the reconstitution of white blood cells (4.45 nL−1, normal range 3.90–10.50 nL−1) with normal
neutrophils (3.03 nL−1, normal range 1.50–7.70 nL−1) and slightly reduced lymphocytes (0.95 nL−1,
normal range 1.10–4.50 nL−1), even though platelets (30 nL−1, normal range 150–370 nL−1) and
haemoglobin (8.9 mg·dL−1, normal range 13.5–17.0 mg·dL−1) were reduced on admission, as well as
almost normal immunoglobulin levels (IgG 6.61 g·L−1, normal range 7.00–16.00 g·L−1; IgA 1.72 g·L−1,
normal range 0.7–4.00 g·L−1; and IgM 0.30 g·L−1, normal range 0.40–2.30 g·L−1) at the time of
HBoV-induced respiratory failure, we judged our patient to be largely immunocompetent. Thus, even
though rare, HBoV must be considered a life-threatening pathogen in adults with atypical pneumonia and




FIGURE 1 Radiomorphological and pathological–anatomical findings of a patient with near-fatal human bocavirus (HBoV) infection. a) Computed
tomography (CT) image after a 7-day course of antibiotic therapy shows bilateral pulmonary infiltrates with interstitial pattern and ground-glass
opacities (3 March 2020). b) HBoV-specific fluorescence in situ hybridisation in lung biopsy. Head and tail HBoV genome regions were detected
with specific fluorescence probes and tissue was counterstained with DAPI. Yellow and orange dots (arrows) indicate codetection of the head and
tail regions of HBoV-DNA. c) Lung biopsy showing fibroblast proliferation (arrows) (haematoxylin and eosin staining). d) Strong infiltration with
T-lymphocytes (CD3 staining in brown) in the lung tissue reflecting excessive immune response. e) Chest radiography (anteroposterior view) at
initiation of glucocorticoid treatment (day 1) showing multifocal opacities in both lungs with foci of consolidation in the upper-left lobe (5 March
2020), and f) at day 4, demonstrating resolution of the multifocal opacities with demarked consolidation in the upper left lobe (8 March 2020).
g) CT image 2 months after treatment demonstrates complete resolution of infiltrates with remaining pre-existing small bullae (26 May 2020).
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Only recently, it has been demonstrated that dexamethasone is beneficial in COVID-19 patients with
respiratory failure requiring respiratory support [3]; however, the benefit of glucocorticoid treatment in
other severe viral respiratory diseases is unclear [4]. In contrast to the dexamethasone scheme used in the
RECOVERY trial in COVID-19 patients (6 mg once daily for up to 10 days), we applied a pulsed
high-dose glucocorticoid therapy scheme deduced from treatment of autoimmune diseases. Notably, the
application of such pulsed “very high-dose” glucocorticoid therapy is supposed to extend the
glucocorticoid mode of action compared to lower doses [5, 6]. We assume that this short-term high-dose
glucocorticoid therapy effectively dampened the detrimental virus-induced immune response, most likely
by glucocorticoid-induced cell death of immune effector cells including infiltrating T-lymphocytes, and
anti-inflammatory effects by modulation of monocyte and macrophage function [7, 8]. Furthermore,
glucocorticoid therapy can inhibit fibroblast proliferation and support the clearance of
inflammation-induced tissue damage [7]. We are aware of glucocorticoid therapy-induced side-effects; that
corticosteroid treatment of ARDS or SARS patients, or patients suffering from viral pneumonia, has
generated conflicting results [4, 5, 9–11]; and that prolonged intake of corticosteroids predisposes to
invasive aspergillosis in the context of severe influenza infection [12]. However, short pulsed high-dose
glucocorticoid therapy has been used for decades for the treatment of various severe autoimmune diseases,
with limited and well-known side-effects [13]. Therefore, we decided to use such a “very high-dose”
short-term scheme and not a lower-dose, longer-lasting scheme for our patient. We believe that in selected
patients, in which the virus-induced immune response is profound and likely to be more harmful to lung
tissue than damage by the virus itself, and in which fatal lung damage has not yet passed the point of no
return, glucocorticoid therapy may preserve lung tissue and function. Notably, most recently, it has been
shown that severe COVID-19 patients benefit from pulsed methylprednisolone administration if given
during the early phase of pulmonary infection [14]. Thus, high-dose glucocorticoid therapy may be
beneficial in patients suffering from severe pulmonary disease caused by HBoV, as demonstrated in our
case, or other viruses.
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